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Steroid hormones including (1,25)-dihydroxyvitamin D3, estrogens, and glucocorticoids control
bone development and homeostasis. We show here that the osteogenic transcription factor
Runx2 controls genes involved in sterol/steroid metabolism, including Cyp11a1, Cyp39a1, Cyp51,
Lss, and Dhcr7 in murine osteoprogenitor cells. Cyp11a1 (P450scc) encodes an approximately
55-kDamitochondrial enzyme that catalyzes side-chain cleavage of cholesterol and is rate limiting
for steroid hormone biosynthesis. Runx2 is coexpressed with Cyp11a1 in osteoblasts as well as
nonosseous cell types (e.g. testis and breast cancer cells), suggesting a broad biological role for
Runx2 in sterol/steroid metabolism. Notably, osteoblasts and breast cancer cells express an ap-
proximately 32-kDa truncated isoform of Cyp11a1 that is nonmitochondrial and localized in both
the cytoplasmand the nucleus. Chromatin immunoprecipitation analyses and gel shift assays show
that Runx2 binds to the Cyp11a1 gene promoter in osteoblasts, indicating that Cyp11a1 is a direct
target of Runx2. Specific Cyp11a1 knockdown with short hairpin RNA increases cell proliferation,
indicating that Cyp11a1 normally suppresses osteoblast proliferation. We conclude that Runx2
regulates enzymes involved in sterol/steroid-related metabolic pathways and that activation of
Cyp11a1 by Runx2may contribute to attenuation of osteoblast growth. (Molecular Endocrinology
23: 849–861, 2009)
Steroid hormones are key regulators of bone developmentand homeostasis (1–10). Systemic deficiency of steroids by
mutations in their cognate steroid hormone receptors [e.g. for
(1,25)-dihydroxyvitamin D3, androgen, and estrogen] or ste-
roid metabolism (e.g. Cyp19 aromatase) decreases mineraliza-
tion, increases bone resorption, and/or inhibits growth plate
closure (5, 11–15). Chronic therapeutic administration of glu-
cocorticoids (3, 16) or natural reductions in steroid hormone
levels (17–21) cause osteoporosis by impairing the metabolic
balance of osteoblasts and bone-resorbing osteoclasts (22–26).
Steroid hormones are prominently produced in selected non-
osseous tissues, but enzymes involved in steroid hormone syn-
thesis and breakdown are endogenously expressed in osteo-
blasts and may locally metabolize steroid precursors into potent
steroid receptor agonists (27–29).
Expression of many steroid hormone-responsive genes in os-
teoblasts is regulated by the Runt-related transcription factor
Runx2/Cbfa1 (6, 30–35), which is essential for osteoblast mat-
uration (36–38). In addition, steroid hormones including 1,25
(OH)2-vitamin D3 and estrogen modulate the expression of
Runx2 at the transcriptional level (39, 40). Furthermore, the
trans-activation function ofRunx2 ismodulated in part by steroid-
related posttranslational mechanisms (41, 42). Other examples
of genetic and gene regulatory interplay between Runx2 and
steroid hormones (e.g. glucocorticoids and estrogens) are also
evident (43, 44).
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The potent osteogenic activity of Runx2 is linked to its prin-
cipal function as an epigenetic regulator of phenotype commit-
ment and cell growth (45–49). Loss of Runx2 deregulates nor-
mal osteoblast growth (47–50), whereas forced expression of
Runx2 suppresses proliferation of osteoblasts (48, 51) and non-
bone cells (52), consistent with its proposed general role as a
gene related to cancer (53). To accommodate its role as a regu-
lator of osteoblast proliferation, the levels of Runx2 oscillate
during the cell cycle and are highest in G1 (48, 54). Multiple
Runx2 target genes have been identified that contribute to os-
teogenic or proliferation-related functions of Runx2 (51, 55–
58), but our understanding of Runx2-responsive genes remains
incomplete.
In this study, we examined whether Runx2 is capable of
controlling genes involved in steroid hormone signaling or me-
tabolism. We identified a panel of genes encoding enzymes that
control sterol metabolism. One of these genes (Cyp11a1) is up-
regulated during osteoblast differentiation and expresses a
unique short Cyp11a1 isoform that, unlike the full-length pro-
tein, is not concentrated into mitochondria. Short hairpin RNA
(shRNA) knockdown of this isoform increases osteoblast pro-
liferation, suggesting Cyp11a1 contributes to Runx2-mediated
attenuation of cell growth.
Results
Identification of Runx2 target genes related to
sterol metabolism
To address whether the biological interrelationships between
Runx2 and steroid hormones are reflected by direct regulatory
pathways, we examined whether Runx2 is capable of control-
ling the expression of genes related to steroid hormone metab-
olism. We have previously used immortalized mouse calvaria
osteoprogenitors derived from Runx2-null mice as a cell culture
model (59) to identify Runx2 target genes during recapitulation
of a developmental transition when proliferating mesenchymal
stem cells become osteoprogenitors and exhibit Runx2-attenu-
ated cell growth (51). Gene expression profiling was used to
assess which genes respond to the introduction of Runx2, a
transcriptionally inert deletion mutant (Runx2361) or a green
fluorescent protein (GFP)-expressing empty vector into Runx2-
null cells. Duplicate RNA samples were harvested from adeno-
virus Runx2 infected cells at 24 h after induction of Runx2 gene
expression and hybridized to Affymetrix mouse cDNA arrays
(Mouse Genome 430 2.0 Array). Statistical analysis of the data
set revealed that a series of genes involved in sterol metabolism
is coordinately controlled by Runx2, along with known Runx2
target genes (Table 1 and Fig. 1).
We tested a representative subset of six genes using quanti-
tative PCR (qPCR) analysis for responsiveness to Runx2 expres-
sion (Fig. 2) in parallel with a prototypical Runx2 target gene
(osteocalcin) as positive control and GAPDH as negative con-
trol. Our results validate Runx2-dependent expression for five
of these six genes (i.e. P450 cytochrome proteins Cyp11a1,
Cyp39A1, and Cyp51 as well as Lss and Dhcr7). Thus, Runx2
modulates a number of genes linked to sterol/steroid metabo-
lism through direct or indirect mechanisms.
Modulation of Cyp11a1 gene expression by Runx2 in
committed osteoblasts
The most prominently modulated sterol-related gene in our
Affymetrix analysis encodes the cholesterol side-cleaving en-
zyme Cyp11a1 (60, 61). Cyp11a1 protein expression is nor-
mally below the level of detection in osteoprogenitors that do
not express Runx2. However, Cyp11a1 mRNA expression is
dramatically induced within 24 h after introduction of Runx2
protein into Runx2-null cells as determined by Affymetrix ex-
pression analysis (Table 1) and qPCR analysis (Fig. 2). To assess
whether Runx2 can up-regulate Cyp11a1 in committed osteo-
blasts, we performed semiquantitative PCR analysis. We ana-
lyzed RNA samples from mouse Runx2-null osteoprogenitors,
mouse MC3T3 osteoblasts, and SV40 transformed human
O4T8 osteoblasts infected with wild-type Runx2 and the corre-
sponding empty adenoviral vector (Fig. 3). The forced expres-
sion of Runx2 rapidly induces Cyp11a1 expression (Fig. 3).
Exogenous Runx2 also stimulates osteocalcin and osteopon-
tin expression but does not alter GAPDH or 18S rRNA levels
(Fig. 3). Thus, Runx2 selectively regulates expression of the
Cyp11a1 gene.
To assess whether CYP11A1 up-regulation by Runx2 is dose
dependent, we transfected Runx2-null cells and MC3T3 cells
with different amounts of a cytomegalovirus (CMV)-based ex-
pression vector encoding Runx2. Runx2-null osteoprogenitors
and immature MC3T3 osteoblasts have very low levels of en-
dogenous Cyp11a1, but Cyp11a1 mRNA levels increase in pro-
portion to the amount of exogenous Runx2 gene induction
(data not shown; see also Fig. 5B below). Taken together,
Runx2 is a key rate-limiting factor for Cyp11a1 gene expression
in both preosteoblastic progenitors and committed osteoblasts.
Cyp11a1 gene expression is induced during
osteoblastic differentiation
We further investigated the physiological relevance of
Cyp11A1 induction by Runx2 by characterizing endogenous
expression of Cyp11a1 during MC3T3 osteoblastic differentia-
tion in relation to endogenous Runx2 levels and other osteoblast
marker genes (Fig. 4A). There is a significant elevation of
Cyp11a1 gene expression throughout the MC3T3 differentia-
tion time course, along with osteocalcin (Fig. 4A) and other
osteoblastic markers (e.g. osteopontin and alkaline phospha-
tase; data not shown). The data show that Cyp11a1 is expressed
at maximal levels in mature osteoblasts in parallel with the
Runx2-dependent expression of the osteocalcin. Hence,
Cyp11a1 is physiologically expressed in differentiated bone cells
that express Runx2.
We also investigated Cyp11a1 expression in Runx2-null
progenitor cells that were reconstituted with wild-type
Runx2 and stimulated to differentiate into the osteoblastic
lineage in the presence of osteogenic medium (Fig. 4B). The
combination of exogenous Runx2 and osteogenic conditions
induces alkaline phosphatase expression (Fig. 4B), and is
known to restore the ability of Runx2-null cells to differen-
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tiate and express other mature osteoblastic markers (59).
Importantly, the presence of Runx2 clearly stimulates
Cyp11a1 gene expression, and this effect becomes more pro-
nounced as differentiation progresses. Thus, Runx2 is rate
limiting for Cyp11a1 gene expression during differentiation
along the osteoblastic lineage.
We analyzed expression of Runx2, Runx1, and Cyp11a1 by
qPCR analysis of total cellular RNA from a panel of osseous and
reproductive tissues. Cyp11a1 mRNA levels are low but detect-
able in calvaria and tibia, where Runx2 is expressed at very high
levels (Fig. 4D). High levels of Cyp11a1 mRNA expression as
well as Runx1 and Runx2 are observed in mature ovary and
TABLE 1. Runx2 regulates a panel of genes related to sterol/steroid hormone synthesis, metabolism and signaling in osteoblasts
Gene symbol Gene name Runx2 WT vs. GFP WT vs. 361
Enzymes involved in sterol
metabolism
Cyp11a1 Cytochrome P450, family 11, subfamily a,
polypeptide 1
4.2 3.9
Lss Lanosterol synthase 3.1 2.7
Dhcr7 7-Dehydrocholesterol reductase 2.3 2.3
Cyp39a1 Cytochrome P450, family 39, subfamily a,
polypeptide 1
2.3 2.7
Hsd3b7 Hydroxy--5-steroid dehydrogenase, 3- and
steroid -isomerase 7
1.7 1.5
Fdps Farnesyl diphosphate synthetase 1.6 1.7
Sult2b1 Sulfotransferase family, cytosolic, 2B, member 1 1.6 1.4
Hsd17b7 Hydroxysteroid (17-) dehydrogenase 7 1.5
Fdxr Ferredoxin reductase 1.5 1.7
Cyp51 Cytochrome P450, family 51 1.6
Sc5d Sterol C5 desaturase 1.5
Ch25 h Cholesterol 25-hydroxylase 2.4
Cyp1b1 Cytochrome P450, family 1, subfamily b,
polypeptide 1
3.0 2.3
Por Cytochrome P450 oxidoreductase 1.6
Cyp20a1 Cytochrome P450, family 20, subfamily a,
polypeptide 1
1.7 1.5
Kinases and gene regulators involved
in sterol metabolism
Stat5a Signal transducer and activator of
transcription 5A
2.0 1.7
Pbx1 Pre B-cell leukemia transcription factor 1 1.8
Prkaa1 Protein kinase, AMP-activated, 1 catalytic
subunit
1.8
Transporters, binding proteins and
receptors involved in sterol
metabolism
Abca2 ATP-binding cassette, subfamily A (ABC1),
member 2
1.7 1.6
Ebpl Emopamil binding protein-like 1.6
Gig1 Glucocorticoid induced gene 1 2.2 1.5
Nr3c1 Nuclear receptor subfamily 3, group c,
member 1
2.0 1.7
Abca1 ATP-binding cassette, subfamily A (ABC1),
member 1
1.9 1.8
Plekhh2 Pleckstrin homology domain containing, family
H, member 2
1.7
Ldlr Low density lipoprotein receptor 1.6 1.6
Osbpl2 Oxysterol binding protein-like 2 1.6 1.6
Osbpl3 Oxysterol binding protein-like 3 1.6 1.5
Osbpl9 Oxysterol binding protein-like 9 1.5
Osbpl8 Oxysterol binding protein-like 8 1.4
Hdlbp High-density lipoprotein binding protein 1.5
Known Runx2 target genes
Spp1 Secreted phosphoprotein 1 (osteopontin) 13.6 23.1
Bglap1 Bone  carboxyglutamate protein 2 (osteocalcin) 6.3 7.7
Mmp13 Matrix metalloproteinase 13 7.8 6.1
Selected genes exhibit a statistically significant increase or decrease in expression 24 h after the infection based on Student’s t test (P  0.05). The data are presented
as a fold change in the expression signal between cells expressing Runx2 wild type (WT) vs. 361 mutant or Runx2 WT vs. GFP. The cluster of steroid signaling- and
metabolism-related genes was extracted by functional annotation clustering of Affymetrix data in the David 2.0 web-based environment (Database for Annotation,
Visualization and Integrated Discovery, http://david.abcc.ncifcrf.gov/).
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testis (Fig. 4D), corroborating previous reports showing robust
Runx1-dependent expression of Cyp11a1 in granulosa cells and
periovulatory follicles in rat and mouse (62, 63). Interestingly,
during fetal development or postnatal testicular development,
total Runx levels correlate with Cyp11a1 expression (data not
shown). Taken together, Runx2 and Runx1 may both regulate
Cyp11a1 during development in osseous and reproductive
tissues.
Runx2 induces a small isoform of Cyp11a1 in osteoblasts
We performed Western blot analysis to assess whether the
increase in Cyp11a1 mRNA expression that we observed trans-
lates into a corresponding induction of Cyp11a1 protein levels.
As expected, forced expression of wild-type Runx2 but not
361 results in robust levels of Cyp11a1 protein (Fig. 5A). Ex-
pression of Cyp11a1 is proportional to the amount of Runx2
expression, indicating that Runx2 titrates Cyp11a1 protein lev-
els (Fig. 5B), consistent with a direct effect of Runx2 on
Cyp11a1 gene transcription (see below). Interestingly, lysates
from testis or prostate tissues yield the expected approximately
55-kDa Cyp11a1 protein, whereas osteoblasts and Runx2-null
osteoprogenitors express primarily an approximately 32-kDa
species upon induction by Runx2 (Fig. 5C). Breast cancer-de-
rived MDA-MB-231 cells express both the 55- and 32-kDa iso-
forms (Fig. 5C). Although the 55-kDa isoform of Cyp11a1 is
normally localized in mitochondria (64, 65), the N-terminally
truncated form of human CYP11A1 (isoform B) lacks the N-
terminal mitochondrial localization signal (66) (GenBank acces-
sion no. NM_001099773 and NP_0010933). Thus, the short
murine Cyp11a1 isoform that is induced by Runx2 may not be
localized in mitochondria (see below).
Expression of the 32-kDa isoform of human Cyp11a1 is
regulated by alternative splicing and utilization of an internal
translational start codon. We examined the distribution of ex-
ons present in mouse Cyp11a1 mRNA using RT-qPCR (Fig. 6).
Cyp11a1 mRNA is clearly expressed endogenously in testis and
upon induction by Runx2 in MC3T3 osteoblasts and Runx2-
null osteoprogenitors. More importantly, exons encoding the
first and second ATG start codon of themouse Cyp11a1mRNA
are detected at comparable abundance in all three RNA samples
(Fig. 6), suggesting that each sample expresses a full-length
Cyp11a1 mRNA. It appears that the murine 32-kDa isoform of
Cyp11a1 is not produced by omission of the first ATG-contain-
ing exon (as is the case for human CYP11A1) but perhaps by
alternative translational initiation.
Cyp11a1 gene is directly regulated by Runx2 at the
promoter level
Forced expression data clearly indicate that Cyp11a1 gene
expression is responsive to modulations in the levels of Runx2
(Figs. 2–4). To investigate whether Runx2 can directly control
Cyp11a1 gene transcription, we first tested whether the induc-
tion of endogenous Cyp11a1 expression requires the DNA
binding and trans-activation functions of Runx2 upon introduc-
tion into Runx2-null cells (Fig. 7A). The data show that
Cyp11a1 is robustly up-regulated by wild-type Runx2 but not
when its C-terminal trans-activation domain is deleted (Runx2
FIG. 2. Validation of Runx2-responsive expression of genes related to sterol/
steroid pathways by qPCR analysis. Real-time qPCR analysis was used to validate
mRNA expression levels of a subset of genes that depend on Runx2 as identified
by Affymetrix analysis (see Table 1). Osteocalcin levels were measured to
establish the inducibility of a representative Runx2-responsive gene. Expression
values for all genes were plotted relative to each other and normalized using
GAPDH as internal control. Error bars represent SE of qPCR data for three
independent experiments.
FIG. 3. Runx2 induces Cyp11a1 expression in mouse and human osteoblasts.
Representative semiquantitative RT-PCR analysis was performed to examine
stimulation of Cyp11a1 by Runx2 in mouse MC3T3 or human HOB-04T8
osteoblasts compared with Runx2-null cells. Levels for Runx2, osteocalcin,
osteopontin, and GAPDH (or 18S) gene transcripts were assessed in parallel. RNA
samples were prepared 24 h after infection with adenoviral vectors that express
wild-type Runx2 or GFP. GAPDH and 18S RNA were used as internal controls for,
respectively, mouse and human samples. RT-PCR products were subjected to
electrophoresis in 2% agarose gels and visualized by ethidium bromide staining.
Digital images were inverted to display black bands on a white background.
Dashed lines indicate noncontiguous lanes on the same gel.
FIG. 1. The schematic representation of the multiple consecutive enzymatic
reactions that are required for the biosynthesis of cholesterol (sterol pathway)
and its conversion to pregnenolone (steroid pathway). Our data show that
several key enzymes of cholesterol biosynthesis and metabolism are expressed in
osteoblasts, and their expression is induced by the bone-specific transcription
factor Runx2.
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mutants 432 and 361) or when its DNA-binding domain
(mutant DBDM) is mutated (Fig. 7A). Hence, transcriptional
activation by Runx2 is critical for induction of Cyp11a1.
Both the mouse and human Cyp11a1 gene promoters con-
tain at least five Runx2 consensus motifs, although their loca-
tions within the respective 5-flanking regions are not strictly
conserved (Fig. 7B). We performed EMSAs to examine whether
these sites can support Runx2 binding in vitro. To permit a
quantitative comparison of relative binding strengths for each of
these sites, we performed competition analyses using unlabeled
oligos spanning the Runx2 motifs and a known probe that en-
compasses a classical Runx2 binding site in the rat osteocalcin
gene (site C or OSE2). Nuclear extracts from rat ROS17/2.8
osteosarcoma cells were used in binding reactions, because these
cells are known to express high endogenous levels of Runx2
and were used to define site C/OSE2 in previous studies (35–
37). The EMSA results show that one motif (Cyp3, nucleo-
tides 1005 to 999) is an effective competitor, and three
motifs are moderately effective competitors (Cyp2, Cyp4,
and Cyp5) (Fig. 7, C and D). The most upstream motif we
tested (Cyp1) did not compete for Runx2 binding to the es-
tablished Runx2 element site C (Fig. 7, C and D). Thus, we
have empirically validated that there is at least one high-
affinity Runx2 site in the mouse Cyp11a1 gene promoter and
that three additional sites may contribute to transcriptional
control of the Cyp11a1 gene.
We next performed transient transfection assays with Cyp11a1
promoter fragments fused to the luciferase promoter. For luciferase
reporters, we selected a promoter fragment spanning about 1.4 kb
of 5 sequence that contains the four validated Runx2 motifs, in-
cluding the high-affinity Runx2 element (Cyp 3) (Fig. 8A). Coex-
pression of Runx2 clearly enhances reporter gene activity of the
1.4-kb Cyp11A gene promoter by about 3- to 4-fold (Fig. 8A).
However, Runx2 does not activate the 0.3-kb Cyp 11A gene
promoter that lacks three Runx2motifs (Cyp2, Cyp 3, and Cyp4),
or the 0.2-kb promoter that does not contain any discernable
Runx2 motifs (Fig. 8A). We note that the single Runx2 site in the
0.3-kb promoter is not sufficient for Runx2-mediated transcrip-
tional stimulation. The transfection data indicate that Runx2 di-
rectly activates Cyp11a1 transcription and that this activation re-
quires cognate sites between1.4 and0.3 kb.
FIG. 4. Runx2-dependent expression of Cyp11a1 during osteoblast maturation.
A, Expression levels of Cyp11a1, Runx2, and osteocalcin RNA levels were
analyzed by qPCR during osteoblast differentiation. Confluent MC3T3 cells were
induced to differentiate with ascorbic acid and -glycerophosphate for 28 d.
Expression values were normalized based on GAPDH mRNA levels. Error bars
represent SE of two independent experiments. B, Expression levels of Cyp11a1
and alkaline phosphatase mRNAs were determined by qPCR in Runx2-null cells in
the presence or absence of exogenous Runx2. Runx2-null cells were infected
with adenovirus expressing Runx2 (Ad-Runx2) or GFP empty vector (Ad-GFP-EV),
and differentiation media was added to cells 24 h after infection. Samples were
prepared at 4-d intervals and analyzed as described in A. C, Levels of Cyp11a1
mRNA in relation to Runx2 and Runx1 mRNAs were determined by qPCR analysis
in adult mouse tissues (2 months of age). Levels of gene expression were
normalized relative to HPRT mRNA. Error bars represent the SD of duplicate qPCR
of a representative experiment.
FIG. 5. Runx2 induces a small Cyp11a1 protein isoform in Runx2-null cells. A,
Western blot analysis shows expression of Cyp11a1 protein in Runx2-null cells
infected (for 36 h) with an adenovirus vector expressing wild-type (WT) Runx2 but
not the Runx2 361 mutant or GFP as indicated. CDK2 protein was used as an
internal control. Dashed lines reflect digital juxtaposition of parallel lanes from the
same gel. The Cyp11a1 species we detected has a molecular mass of about 32 kDa
(see C). B, Dose-dependent stimulation of Cyp11a1 protein expression is evident in
lysates from Runx2-null cells infected (for 36 h) with the indicated amounts of an
adenoviral vector expression wild-type Runx2 protein. Cyp11a1 and Runx2 levels
were detected by Western blot analysis, whereas CDK2 protein levels were used as
an internal control. C, Different Cyp11a1 protein isoforms are expressed in different
cell types and tissues. The full-length approximately 55-kDa Cyp11a1 protein isoform
is expressed in testis and prostate tissues as well as MDA-MB-231 breast cancer cells
but not in Runx2-null cells. Runx2-null cells and HOB-04T8 cells reconstituted with
wild-type Runx2 and MDA-MB-231 cells (that are known to express Runx2
ectopically due to the transformed state of the cells) each express a short
approximately 32-kDa isoform. The low-mobility bands (55 kDa) in the left lane are
not induced by Runx2 and considered nonspecific. When exogenously expressed in
Runx2-null cells, CYP11A1 gives an approximately 55-kDa band, confirming the
antibodies’ specificity (labeled Rx2 null hCYP11A1).
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To provide further in vivo evidence that Cyp11a1 is a direct
Runx2 target, we analyzed Runx2 interactions with the
Cyp11a1 promoter by chromatin immunoprecipitation analy-
sis. Runx2-null cells do not exhibit Runx2 binding to the
Cyp11a1 promoter above background levels (Fig. 8B). Robust
interactions are observed throughout the promoterwhenRunx2
is reintroduced by adenoviral infection (Fig. 8B). Chromatin
immunoprecipitates prepared using an IgG antibody exhibit sig-
nals at or below background levels. We conclude that Cyp11a1
is a Runx2-responsive gene and may represent an integral com-
ponent of a biological program that is controlled by Runx2 to
regulate enzymes mediating sterol/steroid metabolism.
The 32-kDa isoform of Cyp11a1 is not localized
in mitochondria
Forced expression of Runx2 in Runx2-null cells induces a
32-kDa isoform of Cyp11a1 that is shorter than the full-length
55-kDa isoform that is localized in part in mitochondria (see
Fig. 5). To assess the subcellular localization of the 32-kDa
isoform, we performed immunofluorescence microscopy analy-
sis using a Cyp11a1 antibody and find that the localization of
Cyp11a1 varies between MC3T3 osteoblasts and Runx2-null
cells (Fig. 9A). In most MC3T3 cells (85%), we observe diffuse
cytoplasmic/nuclear staining, although perinuclear tubular
(12%) or vesicular (3%) staining patterns are also detected. In
Runx2-null cells, the majority of cells exhibit perinuclear
tubular staining (80%) or diffuse cytoplasmic/nuclear staining
(19%) and rarely cytoplasmic vesicular staining (1%). The spec-
ificity of Cyp11a1 antibodies is indicated by recognition of ex-
ogenously expressed flag and GFP-tagged Cyp11a1 proteins
(see supplemental Fig. S1, published as supplemental data on
The Endocrine Society’s Journals Online web site at http://mend.
endojournals.org). Therefore, similar to the full-length 55-kDa
Cyp11a1 protein, the majority of the 32-kDa protein variant is
expressed in the cytoplasm.
The 55-kDa Cyp11a1 protein is a full-length isoform of
526 amino acids (aa). The 32-kDa short isoform is predicted
to be generated by alternative translation at an internal ATG
to yield a 371-aa protein that is analogous to human
CYP11A1 isoform B. We investigated the subcellular local-
ization of the 371-aa isoform relative to the full-length
526-aa isoform using the exogenous expression of either Flag
epitope-tagged proteins (Fig. 9B) or GFP fusion proteins (Fig.
9C). Consistent with the data obtained using a Cyp11a1 an-
tibody, we find that both short and long isoforms of Cyp11a1
are predominantly localized in the cytoplasm. However, the
Flag-tagged 526-aa variant exhibits mostly a tubular pattern,
whereas the 371-aa has a vesicular pattern. These results
indicate that the two Cyp11a1 isoforms are localized in sep-
arate compartments.
We studied the subcellular localization of the long and short
isoforms using MitoTracker dye, a cell-permeable probe that
selectively labels mitochondria (Fig. 9D). The 526-aa isoform of
Cyp11a1 clearly colocalizes with MitoTracker dye, albeit that
there is also diffuse nonmitochondrial cytoplasmic staining for
Cyp11a1 (Fig. 9D and data not shown). In contrast, the 32-kDa
(371 aa) variant of Cyp11a1 does not colocalize with Mito-
Tracker dye. Taken together, the short isoform of Cyp11a1 does
not reside in mitochondria and may perform a novel cellular
function.
shRNA knockdown of Cyp11a1 increases
osteoblast proliferation
We studied the function of Cyp11a1 by shRNA-mediated
depletion of its endogenous levels in Runx2-null cells orMC3T3
osteoblasts (Fig. 10). shRNA for Cyp11a1 decreases its mRNA
levels with limited effects on the expression of other genes (Fig.
10A) and diminishes Cyp11a1 protein levels (Fig. 10B). In
Runx2 null cells that do or do not express exogenous Runx2,
knockdown of Cyp11a1 causes a statistically significant, albeit
quantitatively modest, increase in cell growth (Fig. 10C). A
comparable stimulatory effect on cell proliferation is observed
upon knockdown of Cyp11a1 expressed endogenously in
MC3T3 cells (Fig. 10D). Thus, consistent with the cell growth-
suppressive potential of Runx2, its target Cyp11a1may support
attenuation of cell proliferation.
Discussion
Runx2 is known to control a number of phenotypic genes that
are coregulated by steroid hormone receptors (31, 32, 67), as
well as genes for steroid receptors (68). In this study, we show
that Runx2 controls a series of genes encoding enzymes involved
FIG. 6. The full-length transcript of Cyp11a1 gene is induced by Runx2 in
osteoblasts. To determine whether the short osteoblast-specific isoform of
Cyp11a1 protein can be generated by alternative transcription or alternative
splicing in mouse, six different pairs of primers for mouse Cyp11a1 gene were
designed spanning the first eight of nine different exons of the gene. qPCR was
performed with the total cDNA synthesized from the random hexamer primers to
measure different Cyp11a1 exons representation in Cyp11a1 transcript induced
by Runx2 in mouse calvaria Runx2-null cells and MC3T3 cells and in the native
transcript from the mouse testis. All pairs of primers amplified comparable levels
of products, indicating that all of the first eight exons of mouse Cyp11a1 gene
are present at the same amount after induction of gene expression by Runx2 in
osteoblasts. The endogenous (noninduced) level of Cyp11a1-specific RNA was
significantly (around 500-fold) lower then Runx2-induced transcript in this
experiment, possibly minimally contributing to the reaction (data not shown).
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in sterol and steroidmetabolism. Cyp11a1, a representative sterol/
steroid-related gene, is directly regulated by Runx2 in osteo-
blasts through Runx2 elements in the Cyp11a1 promoter. The
finding that Runx2 controls expression of sterol-related genes
indicates that Runx2 may locally modulate sterol and steroid
compounds within the osteoblast microenvironment. The bio-
logical relevance of these modulations is reflected
by the importance of cholesterol metabolism in os-
teoblasts and bone homeostasis (69).
Our observation that Cyp11a1 is a Runx2 target
gene complements previous studies that have
shown that Cyp11a1 and Runx1 are coregulated
and that Cyp11a1 is Runx1 responsive in ovulating
follicles (62, 63). Interestingly, data presented here
and in other studies (70) indicate that Runx2 is also
highly expressed in testis, a reproductive tissue in
which Cyp11a1 is also abundantly expressed.
Hence, the Cyp11a1 genemay perhaps be regulated
by any of the three Runx transcription factors, de-
pending on the cell type and tissue context in which
specific Runx members are expressed. We consider
it less likely, nevertheless, that Cyp11a1 induction
by Runx2 may have a systemic endocrine effect.
Cyp11a1 null mice die within the first 2 d after birth
and survive slightly longer than Runx2-null mouse
pups. Both Runx2 and Cyp11a1 null mice exhibit
severe growth retardation. However, unlike
Cyp11a1 knockout mice, Runx2-null mice do not
developmuscular atrophy and gonadal defects (71),
indicating that Runx2 deficiency does not have
dominant effects on circulating hormone levels.
Based on the inhibitory effects of Cyp11a1 in im-
mature osteoblasts and the prominent expression of
Cyp11a1 in late-stage osteoblasts, we propose that
Runx2 control of Cyp11a1 supports metabolic
functions in both proliferating and postprolifera-
tive bone cells (i.e. mature osteoblasts and/or min-
eral-embedded osteocytes).
The full-length Cyp11a1 protein (55 kDa) is
localized in mitochondria. Immunoblotting experi-
ments show that Runx2 up-regulates a short iso-
form (32 kDa) of Cyp11a1 that is localized in
both the cytoplasm and the nucleus but not in mi-
tochondria. AlternativemRNA splicing is known to
generate a short (32 kDa) isoform in human cells,
because the human CYP11A1 gene contains an al-
ternative 5 exon that eliminates the normal ATG,
whereas an internal methionine codon functions as
an alternative ATG start codon. Although this al-
ternative exon is conserved in the primate lineage, it
appears to be absent in the rodent lineage. The trun-
cated mouse Cyp11a1 isoform may be generated
without alternative splicing in mouse cells by alter-
native translational initiation (by preferred recog-
nition of the internal ATG) and/or posttranslational
cleavage.
Because we observe that a subset of the short
32-kDa isoform of Cyp11a1 localizes in the nucleus (supple-
mental Fig. S2), the possibility arises that the function of
Cyp11a1 in mature osteoblasts may be related to metabolism of
sterol and steroid compounds inside the nucleus. Recent data
suggest that Cyp11a1 can hydroxylate vitamin D2 and vitamin
D3 (72–74). At least some of these vitamin D metabolites have
FIG. 7. Transcriptional activation of Cyp11a1 involves promoter recognition by Runx2
protein. A, Cyp11a1 expression is activated by forced expression of wild-type Runx2 protein
but not mutant Runx2 proteins with defects in trans-activation (i.e. C-terminal deletion
mutants 361 and 432) or DNA binding (DBDM). RNA samples were obtained from cells
infected for 40 h with adenoviral vectors expressing the indicated Runx2 proteins. The mRNA
levels of Cyp11a1, Runx2, and osteocalcin were analyzed by qPCR and normalized using
GAPDH as internal control. Error bars indicate SD of two independent experiments. B, Human
and mouse CYP11A1 gene promoters were analyzed for the presence of Runx2 binding
consensus sites (5-HGYGGT-3). C, Runx2 binding to cognate motifs in the mouse Cyp11a1
gene promoter was determined by EMSAs using a radiolabeled probe spanning a classical
Runx2 element (site C or OSE2; oligonucleotide Rx2-C1). Binding reactions were prepared
using protein samples prepared from ROS17/2.8 cells that contain high levels of Runx2
protein. Competition assays were performed by adding 100-fold molar excess of unlabeled
oligonucleotides to the binding reaction. The following competitor oligonucleotides were
used: Rx2-C1 (self-competition), Sp1 consensus (Sp1 con), Rx2-C2 (Runx2 motif in the rat
Runx2 gene) (79), a corresponding mutant oligo in which the Runx2 motif is mutated (Rx2-
C2 mut), and five oligonucleotides that span putative Runx2 motifs in the Cyp11a1 promoter
(respectively, Cyp-1, -2, -3, -4, and -5). Protein-DNA complexes were visualized by
autoradiography of a 6% acrylamide gel (un, unrelated complex). D, Quantitation of the
Runx2-DNA complexes presented in C.
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antiproliferative activities (e.g. reflected by reduced DNA synthe-
sis). Thus, intranuclear production of biologically active vitaminD
compounds by Cyp11a1 may support the antiproliferative prop-
erties of Runx2 in osteoblasts. Indeed, we observed a modest in-
crease in cell proliferation after specific shRNA knockdown of
Cyp11a1 expression, suggesting that induction of Cyp11a1 ex-
pression by Runx2 functionally contributes to Runx2-dependent
attenuation of osteoblast proliferation.
Materials and Methods
Tissue culture and mouse tissues
MC3T3-E1 and Runx2-null cells were grown in MEM from
GIBCO/Invitrogen (Grand Island, NY), catalog item 11900-024. U2OS
human osteosarcoma cells were cultured in McCoy’s 5A medium (Hy-
Clone Laboratories, Inc., Logan, UT), ROS 17/2.8 cells were cultured in
Ham’s F12 medium (HyClone), and HEK293T cells were cultured in
DMEM/high-glucose medium (HyClone). All cell types were main-
tained at 37 C and 5% CO2 humidified atmosphere. Runx2-null cells
are calvarial osteoprogenitor cells derived from Runx2 knockout mice
that were generated by stable mouse telomerase gene (mTERT) integra-
tion in our laboratory as described (59). HOB 04T8 cells represent
T-antigen transformed, conditionally immortalized humanosteoblast cells,
which grow at a permissive temperature of 34 C) as described previously
(75).HOB04T8osteoblastswere grown inDMEM-F12medium (GIBCO/
Invitrogen) at 34 C and 5% CO2 humidified atmosphere.
Media for MC3T3, Runx2-null, U2OS, and HOB cells were supple-
mented with 10% fetal bovine serum (FBS) from Atlanta Biologicals
(Lawrenceville, GA). The medium for ROS cells was sup-
plemented with 5% FBS from HyClone. All media were
also supplemented with 30 mM penicillin-streptomycin
and 100 mM L-glutamine.
For analysis of in vivo gene expression, mouse tissues
were collected in 2 ml Trizol reagent and sonicated for
10–30 sec, and RNA was extracted by standard proto-
cols. All procedures involving the care and use of C57
mice were approved by the Animal Research Committee
at the University of Massachusetts Medical School.
Gene delivery by transfections and infections
For transfections, MC3T3 and Runx2-null cells were
plated in 100-mm plates at a density of 0.4 106 cells per
plate or in six-well plates at a density of 8.3 104 cells per
well. After 24 h, cells were transfected using Lipo-
fectamine Plus reagents according to the manufacturer’s
protocol (Invitrogen, Carlsbad, CA). U2OS cells were
plated at 6.7  104 cells per well in six-well plates and
transfected after 24 h using Fugene 6 transfection reagent
(Roche Diagnostics GmbH, Mannheim, Germany) ac-
cording to the manufacturer’s protocol. Cells were col-
lected 36 h after transfection.
For adenoviral infections, Runx2-null or MC3T3
cells were plated in six-well plates (12.5  104 cells per
well). After 24 h, cells were infected with a 100 multiplic-
ity of infection (MOI) of each virus for Runx2-null cells
and 400 MOI for MC3T3 cells in 600 l medium com-
plemented with 1% FBS for 4 h. Then 400 l MEM
containing 1% FBS medium was added, and cells were in-
cubated for an additional 10 h. HOB cells were plated in
six-well plates (12.5 104 cells per well) and infected after
24 h with 25 MOI of each virus for 4 h in 400 l DMEM-
F12 medium supplemented with 1% FBS. Infection effi-
ciency was monitored by an Independent Ribosomal Entry
Site (IRES)-driven GFP signal.
For shRNA-mediated knockdown of Cyp11a1 ex-
pression, Runx2-null cells were plated in six-well plates (1  105 cells
per well) and infected 24 h later with lentivirus expressing rodent
Cyp11a1 or nonspecific shRNA. Briefly, cells were treated with 1.5 ml
nonpurified virus supernatant frompackaging cells (HEK293T) and 0.5ml
complete fresh MEMper well with a final concentration of 8 g/ml hexad-
imethrinebromide(Polybrene;Sigma-Aldrich, Inc.,St.Louis,MO).Plateswere
centrifuged upon addition of the virus at 1460 g at 37 C for 1 h. Infection
efficiency was monitored by GFP coexpression at 3 d after infection.
Expression constructs and viruses
A pCMV5-Runx2 expression vector was generated by cloning the
mouse Runx2 cDNA (MASNS isoform) into pCMV5. The cDNA of
full-length Runx2 and its deletion mutants 1-361 (C) and 1-432
(432) as well as point mutants R182Q (DNA binding domain mutant)
andHTY426-8AAA (Smad interaction mutant) were each recloned into
an adenoviral vector (AdenoVator TM; Qbiogene, Irvine, CA) from the
corresponding pcDNA vectors. Viruses were generated according to
manufacturer’s protocol (Qbiogene) and purified using an adenovirus
purification kit (Promega, Madison, WI).
Human CYP11A1 full-length cDNA in pCMV-SPORT6-expressing
vector was purchased from Mammalian Genome Collection of the
American Type Culture Collection (Manassas, VA).
A mouse Cyp11a1 cDNA (ENSMUSG 00000032323) was used to
construct an expression vector for both full-length Cyp11a1 and an
N-terminally truncated form (using a 5-deletion starting from nucleo-
tide 50 of exon 3). Both cDNA fragments were amplified by PCR from
mouse testis cDNA with specific primers (Table 2). PCR products were
inserted to TOPOTA PCR cloning vector (Invitrogen) and subsequently
subcloned into the EcoRI restriction site of pCMV-tag2B vector to ob-
tain Cyp11a1 proteins with anN-terminal Flag tag (Stratagene, La Jolla,
FIG. 8. Runx2 directly regulates the mouse Cyp11a1 promoter. A, Runx2 activates the Cyp11a1
promoter and requires a promoter fragment spanning three Runx2 motifs. Luciferase reporter
constructs fused to different Cyp11a1 promoter fragments with different endpoints (i.e. 1.4 kb,
330 bp, and 210 bp) were transfected into Runx2-null cells that express wild-type Runx2, a Runx2
DNA-binding domain mutant, or GFP (negative control). Relative firefly luciferase values were
normalized using renilla luciferase. Error bars represent the standard error of representative
experiments performed in duplicate. B, Chromatin immunoprecipitation analysis shows that
Runx2 binds to multiple sites in the endogenous Cyp11a1 promoter. Runx2 or GFP was
expressed in Runx2-null cells upon adenoviral infection, and Runx2 binding to the promoter
was assessed by qPCR analysis of immunoprecipitates obtained with Runx2 antibody (a Runx2) or
nonspecific IgG. Error bars indicate the SD between duplicate samples of a representative experiment.
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CA) or into pEGFP-C2 vector (Clontech, Mountain
View, CA) to yield an N-terminal GFP tag. All constructs
were sequences to validate the correct reading frame and
absence of mutations.
Rodent Cyp11a1-specific shRNA-expressing lenti-
viral vectors (pGIPz) and nonsilencing RNA in pGIPz
were purchased from Open Biosystems/Thermo Fisher
Scientific (Huntsville, AL). Lentiviruses were packaged
in HEK293T cells by standard procedures. Briefly,
HEK293T cells were seeded at 1  106 cells per 10-cm
plate and cotransfected the next day with 6 g express-
ing plasmid with 4 g of the packaging plasmid pCMV-
dR8.91 and 2 g envelope plasmid pMD2.G using Fu-
gene6 reagent. The medium was changed after 24 h and
11 mg/ml BSA was added. Culture media were col-
lected at 48 or 72 h after transfection and centrifuged at
330  g for 5 min to spin down cell debris. The result-
ing supernatant was used directly for infection of cells.
Proliferation and differentiation experiments
For proliferation assays, Runx2-null calvaria cells were
plated at 105 cells per well in six-well plates and infected
with lentivirus as described above. Cells were passed at d 3
after lentiviral infection and infected the next day with ad-
enoviruses as described. After adenoviral infection for 24 h,
cells were transferred to six-well plates at 105 cells per well.
Growth curves were obtained by cell counting for 4 d.
For differentiation studies, mineralizing MC3T3-E1
cells or Runx2-null cells reconstituted with Runx2 ex-
pressed using an adenoviral vector were plated at a den-
sity of 0.4  106 cells per 100-mm plate in MEM com-
plemented with 30 mM penicillin-streptomycin, 100 mM
L-glutamine, and 10% FBS (Hyclone). Cells were treated
with 10 mM -glycerophosphate and 25 g/ml ascorbic
acid in fresh media at d 4 after plating. The culture me-
diumwas supplemented with 10 mM -glycerophosphate
and 50 g/ml ascorbic acid every other day for the re-
mainder of the experiment.
Western blot analysis
For Western blotting, cell pellets were boiled in 100 l
direct lysis buffer [50mMTris-HCl (pH6.8), 2%SDS, 10%
glycerol, 12% urea, 25 M MG132 (Calbiochem, EMD
Biosciences, Inc., La Jolla, CA), 100 mM dithiothreitol, and
1Complete protease inhibitors (Roche, Nutley, NJ)]. Ali-
quots (5 l) of each lysate were separated using 10% SDS-
PAGE and subjected to semi-wet transfer to polyvinylidene
difluoride membranes (Millipore, Billerica,MA). PBS (1)/
0.1%Tweenwith 5%milkwas used for 1 h to block nonspe-
cific binding. Primary and secondary antibodieswere used in a
1:2000 dilution for 1 h in PBS/0.1%Tween/1%milk. Signals
were detected by chemiluminescence (PerkinElmer Western
Lighting Chemiluminescence Reagent Plus; PerkinElmer,
Waltham, MA). Cyp11a1 rabbit antiserum was a kind gift
of Dr. Walter Miller (Department of Pediatrics, University
of California at San Francisco) (76) and was incubated at
1:1000 dilution at 4 C overnight. Runx2-specific mouse
monoclonal antibodies were the generous gift of Dr. Yoshi
Ito (Institute for Molecular and Cellular Biology, Singa-
pore). CDK2 rabbit polyclonal antibodies (M2) and-actin
goat polyclonal antibodies (C11) were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA).
qPCR analysis
Total RNA was extracted with Trizol reagent (In-
vitrogen) and purified on columns after deoxyribonucle-
FIG. 9. Endogenous Cyp11a1 and the exogenous 371-aa isoform of Cyp11a1 exhibit similar
intracellular localization in osteoblasts. A, Micrograph of endogenous Cyp11a1 protein present in
Runx2-null osteoprogenitors and MC3T3 cells detected using in situ immunofluorescence. Cyp11a1
exhibits either punctuate perinuclear or weak nuclear staining in the majority of the cells. B,
Intracellular localization of exogenously expressed Flag-Cyp11a1 fusion proteins in osteoblasts as
detected with immunofluorescence staining of the Flag tag. Cells were transfected with either Flag-
Cyp11a1-expressing constructs or empty vector control and then fixed and stained for the Flag-
epitope and DAPI at 36 h after transfection. The full-length (526-aa) Cyp11a1 protein is localized in
the cytoplasm as reflected by diffuse or tubular staining patterns. The truncated (371-aa) Cyp11a1
isoform has both nuclear and cytoplasmic localization and exhibits a more punctuate pattern. In some
cells, Cyp11a1 foci are concentrated around the nucleus similarly to endogenous protein, whereas in
other cells, they are distributed equally throughout cytoplasm. Cells transfected with the Flag-empty
vector control did not have any detectable staining (data not shown). C, Intracellular localization of
exogenously expressed N-terminal GFP-Cyp11a1 fusion proteins in osteoblasts. Cells were transfected
with constructs expressing either full-length or truncated GFP-Cyp11a1 fusion proteins or control
empty vector expressing GFP alone. Cells were fixed and stained for DAPI for visualization of the
nucleus at 36 h after transfection. The intrinsic fluorescent signals of GFP fusion proteins were
detected in these experiments. Both short and long isoforms of Cyp11a1 when fused to GFP have
clear punctate cytoplasmic localization, with the short form concentrating mostly around the nucleus.
D, Full-length (526 aa) but not truncated (371 aa) Cyp11a1 protein localizes to mitochondria. U2OS
cells were transfected with Flag-Cyp11a1-expressing constructs. After 36 h, Mitotracker dye was
added to the cells for 15 min, followed by fixing and staining of cells for the Flag tag and DAPI.
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ase I treatment (RNA purification kit; Zymogen, Orange, CA). Total
RNA aliquots (1 g) were used for reverse transcription with random
hexamers (Invitrogen). The resulting cDNA products were diluted from
five to 75 times, and 5 l was added in a 25-l qPCR with Power SYBR
Green PCRMasterMix (Applied Biosystems, Foster City, CA) for quan-
titation in an ABI Prism 7000 Sequence Detection System. PCR was
performed using the following conditions: one cycle at 95 C for 10 min
as the initial denaturation and 40 cycles of two-step reaction at 95 C for
15 sec (denaturation) and 60 C for 1 min (annealing and synthesis). The
specific primers were used at a concentration of 0.5 pmol/l in each
reaction (Table 2).
Data normalization of samples from cell lines was established by
qPCR with primers specific for rodent GAPDH and human 18S
rRNA (Applied Biosystems). Primers to the mouse HPRT gene were
used for normalization of qPCR data from different tissue samples.
The same primers and conditions were used for representative semi-
quantitative RT-PCR except that only 25–30 cycles of synthesis were
applied to avoid product saturation. Aliquots of the resulting prod-
uct (5–20 l) were visualized in 2% agarose gels by ethidium bromide
staining.
In situ immunofluorescence
Immunofluorescence microscopy was performed according to
standard procedures. Briefly, cells were grown on gelatin-coated cov-
erslips and transfected or infected as described above, and 36 h after
cells were fixed with 3.8% formaldehyde in PBS for 10 min and
permeabilized with 0.25% Triton X-100 in PBS for 20 min. Nonspe-
cific binding was blocked for 20 min with PBSA solution (PBS con-
taining 0.5% BSA). The following primary antibodies were used for
staining: rabbit antiserum to Cyp11a1 from Chemicon/Millipore
(Chemicon International, Inc., Temecula. CA; catalog item 1294), at
a dilution of 1:300 in PBSA at 37 C for 1 h and mouse monoclonal
antibodies to Flag tag peptide from Sigma (clone M2, catalog item
F1804) at a 1:1000 dilution at 37 C for 1 h. Secondary goat anti-
mouse 488 (green) and goat antirabbit 568 (red) or goat antirabbit 488
(green) (Molecular Probes/Invitrogen, Eugene,OR) antibodieswere used at
a 1:800 dilution in PBSA for 1 h at 37 C. After the 4,6-diamidino-2-
phenylindole (DAPI) staining for 5 min for visualization of cell nuclei,
coverslips were washed with PBS and mounted to the slides with Pro-long
Gold mounting medium (Invitrogen). Double staining for Cyp11a1 and
mitochondria was carried out using the Cyp11a1 antiserum and a mito-
chondrial marker (MitoTracker Red CMXRos from Invitrogen/Molecular
Probes; catalog number M7512) according to protocols provided by the
manufacturer. Fluorescence imageswere takenonanAxioplan2CarlZeiss
fluorescencemicroscope (Carl Zeiss, Thornwood,NY)with aHamamatsu
C4742-95 digital camera (Hamamatsu, Bridgewater, NJ). Digital images
were acquired within the MetaMorph Imaging Series software environ-
ment (version 7.1.3) (Molecular Devices, Sunnyvale, CA).
Chromatin immunoprecipitation assay
Runx2-null calvaria cells were infected for 30 h with adenoviral
vectors expressing Runx2 wild-type and IRES-GFP or GFP alone.
Cells were then cross-linked with 1% formaldehyde for 10 min at
room temperature followed by chromatin immunoprecipitations us-
ing Runx2 rabbit polyclonal antibodies M70 (Santa Cruz) as de-
scribed previously (77). The primer pairs used for amplification of
Runx2-bound fragments within the mouse Cyp11a1 promoter are
listed in Table 2. Primers within the mouse GAPDH gene promoter
were used as negative control.
Reporter gene assays
The 1.4-kb upstream sequence of the mouse Cyp11a1 gene
(ENSMUSG 00000032323) was amplified with specific primers and
cloned into the XhoI/HindIII sites of the pGL4 vector (Promega,
Madison, WI). Subsequently,0.3- and0.2-kb promoter deletions
were obtained by amplifying corresponding fragments, and the re-
sulting PCR products were recloned into the XhoI-HindIII sites of
pGL4. The sequences of specific primers that were used for promoter
cloning are listed in Table 2. For reporter assays, Runx2-null mouse
calvaria cells were seeded at 105 cells perwell of a six-well plate. After 24 h,
cells were infected with adenovirus expressing Runx2, its DNA-binding
mutant, or GFP-expressing empty vector as described above. Cells were
transfected 24 h after infection with each reporter construct (200 ng/well)
and a renilla luciferase reporter vector (20 ng/well) (phRL-null; Promega)
using Lipofectamine/Plus transfection reagents (Invitrogen). Luciferase ac-
tivity was detected in cell lysates 24 h after transfection using the dual
luciferase reporter system from Promega.
EMSA
ROS 17/2.8 cells were cultured to 90% of confluence and har-
vested in ice-cold PBS buffer by scraping. Cell pellets were lysed, and
nuclear extracts prepared as previously described (78). Protein con-
centrations were determined by the Bradford method (Pierce Chem-
ical Co., Rockford, IL). Sense and antisense oligonucleotides span-
ning a classical Runx2 motif (Rx2-C1) were end-labeled with
[-32P]ATP by use of T4 polynucleotide kinase (New England Bio-
labs, Beverly, MA) as documented in previous studies (78). Wild-type
and mutant oligonucleotides (double stranded) were used as compet-
itors. Nuclear protein extracts (5 g) were incubated for 30min at room
temperature with 1 g nonspecific competitor DNA poly (alternating dI-
dC  dI-dC) (Pharmacia, Piscataway, NJ) and 80,000 cpm labeled oligonu-
cleotides. Competition assays were performed by adding 100-fold molar
FIG. 10. shRNA-mediated knockdown of Cyp11a1 affects proliferation of
osteoprogenitors. Cyp11a1 expression was knocked down with specific
shRNAs delivered by lentiviral infection in Runx2-null mouse calvaria cells.
Cells were passed 3 d later and infected with adenovirus expressing Runx2
(Ad-Runx2) or GFP-control virus (Ad-GFP) to induce Cyp11a1 gene expression
in cells already treated with Cyp11a1 shRNA (shCyp) or nonspecific RNA
control (NS). Cells were passed at identical density at 24 h after infection, and
cell proliferation was monitored for the next 4 d. Runx2 overexpression and
Cyp11a1 knockdown levels were monitored by qPCR (A) and Western blot
analysis (B) at d 2 after adenoviral infection. C, Knockdown of Cyp11a1 after
its induction by Runx2 modestly increases cell proliferation. Growth curves
were obtained by cell counting. Error bars represent the SE among four
different wells (from two experiments performed in duplicate). D Knockdown
of endogenous Cyp11a1 increases cell proliferation. MC3T3 cells were
infected with shRNA-lentivirus to knock down endogenous Cyp11a1 protein
levels. Cells were replated after 3 d and counted for the next 4 d. Error bars
represent SE among four different wells.
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excess of unlabeled oligonucleotides to the binding reaction. Protein-DNA
complexes were separated in native 6%polyacrylamide gels and visualized
by autoradiography of the dried gels.
The sequences of double-stranded cDNA oligonucleotides used in
EMSA are listed in Table 2 (only the sense strand is shown, Runx2
motifs are underlined; mutations are shown in italics).
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TABLE 2. Nucleotide sequences of the primers
Primers Forward (5–3) Reverse (5–3)
RT-PCR and qPCR primers
Mouse Runx2 CGA CAG TCC CAA CTT CCT GT CGG TAA CCA CAG TCC CAT CT
Mouse osteocalcin CTG ACA AAG CCT TCA TGT CCA A GCG CCG GAG TCT GTT CAC TA-3
Mouse Cyp11a1 exons 1/2 AGT GGC ACA CAG AAA ATC CA TGG GGT CCA CGA TGT AAA CT
Mouse Cyp11a1 exons 2/3 CCA TTG GGG TCC TGT TTA AG GGG GCA CGA AGT TCT TGA T
Mouse Cyp11a1 exons 3/4 TTC CTT TGA GTC CAT CAG CA CAC TGG TGT GGA ACA TCT GG
Mouse Cyp11a1 exons 4/5 CTG CCT GGG ATG TGA TTT TC CCC CAG GAG GCT ATA AAG GA
Mouse Cyp11a1 exons 5/6 CAG GCC AAC ATT ACC GAG AT CGC AGC ATC TCC TGT ACC TT
Mouse Cyp11a1 exons 6/8 TTG GTT CCA CTC CTC AAA GC GGC AAA GCT AGC CAC CTG TA
Mouse osteopontin ACT CCA ATC GTC CCT ACA GTC G TGA GGT CCT CAT CTG TGG CAT
Mouse Runx1 AGA TTC AAC GAC CTC AGG TTT GTC CGG ATT TGT AAA GAC GGT GAT G
Mouse Cyp39a1 CAG TGT CCT GGA AGG TGG TT GCT TTG GTA ATG GGT CCA GA-3
Mouse Cyp51 TCT CCA ATT CCA TTC CTT GG GCC CAC CAT GGT AAA GCT AA-3
Mouse Dhcr7 TGG CTG CCC TAC CTC TAC AC TAG TAA CCC ACG AGG CCA AG
Mouse Fdps TCG TCA AGG TGC TGA CTG AG CCG GTT GTA CTT GCC TCC TA
Mouse Lss CGA CAT CAC TGC TCA GGA GA TGG CAC AGG ACT TGT TGA AG
Mouse HPRT CAG GCC AGA CTT TGT TGG AT TTG CGC TCA TCT TAG GCT TT
Human osteocalcin GGC AGC GAG GTA GTG AAG AG CGA TAG GCC TCC TGA AAG C
Human CYP11A1 AGT CCA CCT TCA CCA TGT CC GAG AAG GGC CAC ATC TTC AG
Human osteopontin ACA CAT ATG ATG GCC GAG GT ATG GCC TTG TAT GCA CCA TT
CHIP primers
Cyp11a1 1447 AGA CAC CCT GCT TTT CAT AAG G CGG TTT GCT TGT TTT CCA TT
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GAPDH GTG CAT AGA GCC TCG GTA GG CAG ATG AAC AGG GTG GGA AG-3
Primers used for cloning
Cyp11a1 promoter, 1,400 bp ATA AGG AAA ATA ATG TGT TA AGG TTT GGG GCA GAG ACA CT
Cyp11a1 promoter, 300 bp GAT CTC GAG CAT GAG CCA GGA GGT CTA CGG AAG CTT AGT GTC TCT GCC CCA AAC
Cyp11a1 promoter, 200 bp AAT CTC GAG AGG CCT GGA GCT GCC TG CGG AAG CTT AGT GTC TCT GCC CCA AAC
Cyp11a1, 526 aa CGC GAA TTC ATG CTG GCT AAA GGA CTT TC GAT CTC GAG GCC TTC AGT TCA CAG TGT TG
Cyp11a1, 363 aa CGC GAA TTC ATG GCG CCT GGA GCC ATC AA CAT CTC GAG CAT GGG CCA CCT CCC CAT GT
EMSA oligos
Rx2-C1 GTC ACC AAC CAC AGC ATC CTT TG
Sp1-con ATT CGA TCG GGG CGG GGC GAG C
Rx2-C2 GGT CAC AAA CCA CAT GAT TCT GTC TC
Rx2-C2mut GGT CAC AAg tCA CAT GAT TCT GTC TC
Cyp-1 GTG TTA GAA AGA CCA CAA ATT TTT CTT
Cyp-2 TCT GAA GGA TAG TGG TCT TAG GGA CCC
Cyp-3 CTG AGC TGG ATG TGG TAG AAC ATA GGT
Cyp-4 TTT CTG TCA TAG TGG TGA ATG CAT ATA
Cyp-5 GAG ATG GTT CAG TGG TTA AGA GCA CTG
For EMSA oligos, only the sense strand is shown. Runx2 motifs are underlined; mutations are shown in italics.
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